MicroRNA‑204 plays a role as a tumor suppressor in Newcastle disease virus‑induced oncolysis in lung cancer A549 cells

Liang,Ying; Tian,Wen-Yu; Huang,Juan-Juan; Gao,Ling-Xi; Fan,Xiao-Hui

doi:10.3892/ol.2021.12743

MicroRNA‑204 plays a role as a tumor suppressor in Newcastle disease virus‑induced oncolysis in lung cancer A549 cells

Authors:
- Ying Liang
- Wen-Yu Tian
- Juan-Juan Huang
- Ling-Xi Gao
- Xiao-Hui Fan
View Affiliations

Affiliations: Department of Microbiology, School of Preclinical Medicine, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, Department of Clinical Laboratory, Tianjin Children's Hospital, Tianjin 300000, P.R. China
Published online on: April 21, 2021 https://doi.org/10.3892/ol.2021.12743
Article Number: 482
Copyright: © Liang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor development and progression are closely associated with various microRNAs (miRNAs/miRs). We have previously shown that Newcastle disease virus (NDV) strain 7793 induces oncolysis in lung cancer. However, how NDV exerts its oncolytic effect on lung cancer remains to be investigated. The present study assessed the role of miR‑204 in the NDV‑induced oncolysis of lung cancer A549 cells by oncolysis induction in vitro. miR‑204 was significantly upregulated in NDV‑treated A549 cells. Overexpression or inhibition of miR‑204 was significantly associated with NDV‑induced oncolysis in A549 cells. Caspase‑3 and Bax, major regulators of the apoptosis pathway, were regulated by miR‑204, and the association between caspase‑3‑related apoptosis and miR‑204 was identified in NDV‑mediated oncolysis. These data demonstrated that miR‑204 as a tumor suppressor played a role in NDV‑induced oncolysis in lung cancer cells. The present study demonstrates the potential of strategies using miRs to improve oncolytic NDV potency, and highlights miR‑204 as a tumor suppressor in NDV‑induced oncolysis of lung cancer cells.

View Figures

View References

1	Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
2	Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current therapies and new targeted treatments. Lancet. 389:299–311. 2017. View Article : Google Scholar : PubMed/NCBI
3	Adam V, Dooms C and Vansteenkiste J: Lung cancer at the intensive care unit: The era of targeted therapy. Lung Cancer. 89:218–221. 2015. View Article : Google Scholar : PubMed/NCBI
4	Fournier P and Schirrmacher V: Oncolytic Newcastle disease virus as cutting edge between tumor and host. Biology (Basel). 2:936–975. 2013.PubMed/NCBI
5	Lam HY, Yeap SK, Pirozyan MR, Omar AR, Yusoff K, Abd-Aziz S and Alitheen NB: Corrigendum to ‘Safety and clinical usage of Newcastle disease virus in cancer therapy’. BioMed Res Int. 2017:45294372017. View Article : Google Scholar : PubMed/NCBI
6	Batliwalla FM, Bateman BA, Serrano D, Murray D, Macphail S, Maino VC, Ansel JC, Gregersen PK and Armstrong CA: A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med. 4:783–794. 1998. View Article : Google Scholar : PubMed/NCBI
7	Cassel WA and Murray DR: A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother. 9:169–171. 1992.PubMed/NCBI
8	Schirrmacher V, van Gool S and Stuecker W: Breaking therapy resistance: An update on oncolytic Newcastle disease virus for improvements of cancer therapy. Biomedicines. 7:662019. View Article : Google Scholar : PubMed/NCBI
9	Cuadrado-Castano S, Sanchez-Aparicio MT, García-Sastre A and Villar E: The therapeutic effect of death: Newcastle disease virus and its antitumor potential. Virus Res. 209:56–66. 2015. View Article : Google Scholar : PubMed/NCBI
10	Keshavarz M, Nejad ASM, Esghaei M, Bokharaei-Salim F, Dianat-Moghadam H, Keyvani H and Ghaemi A: Oncolytic Newcastle disease virus reduces growth of cervical cancer cell by inducing apoptosis. Saudi J Biol Sci. 27:47–52. 2020. View Article : Google Scholar : PubMed/NCBI
11	Xu Q, Rangaswamy US, Wang W, Robbins SH, Harper J, Jin H and Cheng X: Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo. Int J Cancer. 146:531–541. 2020. View Article : Google Scholar : PubMed/NCBI
12	Jarahian M, Watzl C, Fournier P, Arnold A, Djandji D, Zahedi S, Cerwenka A, Paschen A, Schirrmacher V and Momburg F: Activation of natural killer cells by Newcastle disease virus hemagglutinin-neuraminidase. J Virol. 83:8108–8121. 2009. View Article : Google Scholar : PubMed/NCBI
13	Washburn B, Weigand MA, Grosse-Wilde A, Janke M, Stahl H, Rieser E, Sprick MR, Schirrmacher V and Walczak H: TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus. J Immunol. 170:1814–1821. 2003. View Article : Google Scholar : PubMed/NCBI
14	Koks CA, Garg AD, Ehrhardt M, Riva M, Vandenberk L, Boon L, De Vleeschouwer S, Agostinis P, Graf N and Van Gool SW: Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int J Cancer. 136:E313–E325. 2015. View Article : Google Scholar : PubMed/NCBI
15	Ors-Kumoglu G, Gulce-Iz S and Biray-Avci C: Therapeutic microRNAs in human cancer. Cytotechnology. 71:411–425. 2019. View Article : Google Scholar : PubMed/NCBI
16	Li P, Wang Q and Wang H: MicroRNA-204 inhibits the proliferation, migration and invasion of human lung cancer cells by targeting PCNA-1 and inhibits tumor growth in vivo. Int J Mol Med. 43:1149–1156. 2019.PubMed/NCBI
17	Guo W, Zhang Y, Zhang Y, Shi Y, Xi J, Fan H and Xu S: Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer. Int J Mol Med. 36:1720–1726. 2015. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Ghrici M, El Zowalaty M, Omar AR and Ideris A: Induction of apoptosis in MCF-7 cells by the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus Malaysian strain AF2240. Oncol Rep. 30:1035–1044. 2013. View Article : Google Scholar : PubMed/NCBI
20	Li N, Guo X, Liu L, Wang L and Cheng R: Molecular mechanism of miR-204 regulates proliferation, apoptosis and autophagy of cervical cancer cells by targeting ATF2. Artif Cells Nanomed Biotechnol. 47:2529–2535. 2019. View Article : Google Scholar : PubMed/NCBI
21	Raihan J, Ahmad U, Yong YK, Eshak Z, Othman F and Ideris A: Regression of solid breast tumours in mice by Newcastle disease virus is associated with production of apoptosis related-cytokines. BMC Cancer. 19:3152019. View Article : Google Scholar : PubMed/NCBI
22	Ghosh S: Cisplatin: The first metal based anticancer drug. Bioorg Chem. 88:1029252019. View Article : Google Scholar : PubMed/NCBI
23	Dimitrov KM, Afonso CL, Yu Q and Miller PJ: Newcastle disease vaccines - A solved problem or a continuous challenge? Vet Microbiol. 206:126–136. 2017. View Article : Google Scholar : PubMed/NCBI
24	Yurchenko KS, Zhou P, Kovner AV, Zavjalov EL, Shestopalova LV and Shestopalov AM: Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model. PLoS One. 13:e01954252018. View Article : Google Scholar : PubMed/NCBI
25	Lazar I, Yaacov B, Shiloach T, Eliahoo E, Kadouri L, Lotem M, Perlman R, Zakay-Rones Z, Panet A and Ben-Yehuda D: The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin. J Virol. 84:639–646. 2010. View Article : Google Scholar : PubMed/NCBI
26	Al-Shammari AM, Salman MI, Saihood YD, Yaseen NY, Raed K, Shaker HK, Ahmed A, Khalid A and Duiach A: In vitro synergistic enhancement of Newcastle disease virus to 5-fluorouracil cytotoxicity against tumor cells. Biomedicines. 4:32016. View Article : Google Scholar : PubMed/NCBI
27	Kalyanasundram J, Hamid A, Yusoff K and Chia SL: Newcastle disease virus strain AF2240 as an oncolytic virus: A review. Acta Trop. 183:126–133. 2018. View Article : Google Scholar : PubMed/NCBI
28	Zhang CX, Ye LW, Liu Y, Xu XY, Li DR, Yang YQ, Sun LL and Yuan J: Antineoplastic activity of Newcastle disease virus strain D90 in oral squamous cell carcinoma. Tumour Biol. 36:7121–7131. 2015. View Article : Google Scholar : PubMed/NCBI
29	Zhang S, Gao L, Thakur A, Shi P, Liu F, Feng J, Wang T, Liang Y, Liu JJ, Chen M, et al: miRNA-204 suppresses human non-small cell lung cancer by targeting ATF2. Tumour Biol. 37:11177–11186. 2016. View Article : Google Scholar : PubMed/NCBI
30	Jiang D, Li M, Yu Y, Shi H and Chen R: microRNA-34a aggravates coxsackievirus B3-induced apoptosis of cardiomyocytes through the SIRT1-p53 pathway. J Med Virol. 91:1643–1651. 2019. View Article : Google Scholar : PubMed/NCBI
31	Geekiyanage H and Galanis E: MiR-31 and miR-128 regulates poliovirus receptor-related 4 mediated measles virus infectivity in tumors. Mol Oncol. 10:1387–1403. 2016. View Article : Google Scholar : PubMed/NCBI
32	Rovira-Rigau M, Raimondi G, Marín MA, Gironella M, Alemany R and Fillat C: Bioselection reveals miR-99b and miR-485 as enhancers of adenoviral oncolysis in pancreatic cancer. Mol Ther. 27:230–243. 2019. View Article : Google Scholar : PubMed/NCBI
33	Li T, Pan H and Li R: The dual regulatory role of miR-204 in cancer. Tumour Biol. 37:11667–11677. 2016. View Article : Google Scholar : PubMed/NCBI
34	Santoni G, Morelli MB, Santoni M, Nabissi M, Marinelli O and Amantini C: Targeting transient receptor potential channels by MicroRNAs drives tumor development and progression. Adv Exp Med Biol. 1131:605–623. 2020. View Article : Google Scholar : PubMed/NCBI
35	Tajbakhsh A, Mokhtari-Zaer A, Rezaee M, Afzaljavan F, Rivandi M, Hassanian SM, Ferns GA, Pasdar A and Avan A: Therapeutic potentials of BDNF/TrkB in breast cancer; current status and perspectives. J Cell Biochem. 118:2502–2515. 2017. View Article : Google Scholar : PubMed/NCBI
36	Wang X, Jia Y, Wang X, Wang C, Lv C, Li X, Chu Z, Han Q, Xiao S, Zhang S, et al: MiR-375 has contrasting effects on Newcastle disease virus growth depending on the target gene. Int J Biol Sci. 15:44–57. 2019. View Article : Google Scholar : PubMed/NCBI
37	Trobaugh DW and Klimstra WB: MicroRNA regulation of RNA virus replication and pathogenesis. Trends Mol Med. 23:80–93. 2017. View Article : Google Scholar : PubMed/NCBI
38	Bian J, Wang K, Kong X, Liu H, Chen F, Hu M, Zhang X, Jiao X, Ge B, Wu Y, et al: Caspase- and p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells by Newcastle disease virus. Arch Virol. 156:1335–1344. 2011. View Article : Google Scholar : PubMed/NCBI
39	Yan Y, Liang B, Zhang J, Liu Y and Bu X: Apoptotic induction of lung adenocarcinoma A549 cells infected by recombinant RVG Newcastle disease virus (rL-RVG) in vitro. Mol Med Rep. 11:317–326. 2015. View Article : Google Scholar : PubMed/NCBI
40	Lamkanfi M and Kanneganti TD: Caspase-7: A protease involved in apoptosis and inflammation. Int J Biochem Cell Biol. 42:21–24. 2010. View Article : Google Scholar : PubMed/NCBI